Sumitomo Mitsui Trust Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-14,850	Closed	-$794K	–	1153
2020 Q4	$794K	Hold	14,850	–	–	﹤0.01%	1019
2020 Q3	$613K	Sell	14,850 -42,890	-74%	-$1.85M	﹤0.01%	1017
2020 Q2	$2.8M	Buy	+57,740	New	+$2.77M	﹤0.01%	847
2020 Q1	–	Sell	-32,929	Closed	-$1.41M	–	1096
2019 Q4	$1.41M	Buy	+32,929	New	+$1.43M	﹤0.01%	926

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sumitomo Mitsui Trust Group's ACAD Position: Q1 2021 in Review

Sumitomo Mitsui Trust Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 14,850 shares — an estimated $794K sold.

Sumitomo Mitsui Trust Group first reported a position in ACAD in Q4 2019 and held it in 4 quarters. The position peaked at $2.8M in Q2 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

Sumitomo Mitsui Trust Group reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Sumitomo Mitsui Trust Group sold 14,850 Acadia Pharmaceuticals shares in Q1 2021, an estimated $794K.
Sumitomo Mitsui Trust Group first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 4 quarters.
Sumitomo Mitsui Trust Group's Acadia Pharmaceuticals position peaked at $2.8M in Q2 2020.
272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2021, filed 30 Apr 2021.